Scientist Who Had Claimed Stem Cell Breakthrough Resigns From Japanese Research Institute
By Martin Fackler,
The New York Times
| 12. 19. 2014
Untitled Document
TOKYO — In a blow to the prestige of Japan’s scientific community, a government-backed research institute accepted the resignation of one of its highest-profile scientists on Friday after she failed to replicate research results that were once hailed as a breakthrough in stem cell research.
The institute, Riken, had given the researcher, Haruko Obokata, 31, three months to repeat the experiments that were the basis for her claimed discovery earlier this year of a remarkably simple way to make stem cells, a type of cell that could hold the key to futuristic medical treatments. On Friday, the institute announced that she had failed to replicate a new type of stem cell known as STAP cells, for stimulus-triggered acquisition of pluripotency, a term that refers to the cells’ ability to turn into any other type of cell.
That ability allows stem cells to grow into any kind of cell, like muscle and brain cells. By appearing to offer an easier way to make stem cells, Ms. Obokata’s claimed discovery of STAP cells seemed to bring doctors a step...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...